This Solicitation opportunity from Government of Canada was posted on October 19, 2022. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
DEVELOPMENT OF AN EFFECTIVE MRNA-BASED AFRICAN SWINE FEVER VACCINE
Closed
39903-230304/ACanadaSubmission Closed
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
General Info
Agency
Government of Canada → Public Works and Government Services CanadaView Agency
NAICS
N/A
Place of Performance
*Alberta *Manitoba, CANSet-Aside
NONE
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
PhaseClosed
Submission Closed
Organization & Contact Information
Show more
AgencyGovernment of Canada → Public Works and Government Services Canada
Contacts1 person available
OfficeN/A
Organization / Agency
Government of Canada → Public Works and Government Services Canada
View Agency ProfileOffice AddressN/A
Contacts
Full Description
Show more
Trade Agreement: Canadian Free Trade Agreement (CFTA)
Tendering Procedures: The bidder must supply Canadian goods and/or services
Competitive Procurement Strategy: Best Overall Proposal
Comprehensive Land Claim Agreement: No
Nature of Requirements:
1. TITLE:
DEVELOPMENT OF AN EFFECTIVE MRNA-BASED AFRICAN SWINE FEVER VACCINE THAT CAN DIFFERENTIATE VACCINATED FROM INFECTED ANIMALS
2. SECURITY:
There is no security requirement associated with the requirement.
3. REQUIREMENT:
The Canadian Food Inspection Agency has a requirement for the Development of an effective mRNA-based African swine fever vaccine that can differentiate vaccinated from infected animals.
African swine fever (ASF) is a highly-fatal, hemorrhagic viral disease that affects members of the Suidae family. Currently, there is no commercially effective vaccine or treatment for ASF and therefore it can have devastating consequences for swine industry in ASF free countries due to high mortality and trade restrictions.
Currently the most effective experimental vaccines for ASF are live attenuated vaccines. Multiple different live attenuated vaccines have been demonstrated to provide protection against ASF. Despite their ability to elicit protective immunity, these vaccines suffer from several drawbacks. Messenger RNA (mRNA) based vaccines have been able to elicit protective immunity consisting of both antibody and cellular immunity in both humans and pigs.
mRNA vaccines can be generated in three different forms; conventional, self-amplifying or trans-amplifying. In order to decide the best form of mRNA vaccine that will work in pigs, we will first express the highly immunogenic ASFV protein p72. Antibodies to ASFV p72 will be measured using serological assays (ELISA).
Objective: In this study we propose to generate an mRNA vaccine which express 15 different antigens of ASFV, and test them in vaccination-challenge experiments at the National Centre for Foreign Animal disease (NCFAD), Winnipeg, Canada. The mRNA vaccines will be designed, produced and supplied to the NCFAD by a contractor.
To qualify a bid will have to consist of no less than 80% of goods and/or services of Canadian origin.
4. EVALUATION AND SELECTION:
Mandatory technical evaluation criteria are included in Annex "C" of the solicitation.
A bid must comply with the requirements of the bid solicitation and meet all mandatory technical evaluation criteria to be declared responsive. The responsive bid with the lowest evaluated price will be recommended for award of a contract.
5. OWNERSHIP OF INTELLECTUAL PROPERTY:
Any intellectual property arising from the performance of the Work under the Contract will vest in Canada.
6. PERIOD OF CONTRACT:
It is anticipated the contract will be effective from date of award to 2023-12-31.
------------------------------------------------------------------ Contracting Authority
Lorraine Jenkinson Procurement Specialist Public Works and Government Services Canada Procurement Branch, Western Region Canada Place, Suite 1000 9700 Jasper Avenue NW Edmonton AB, T5J 4C3
Telephone: 587-337-2458 Facsimile: 780-497-3510 E-mail address: lorraine.jenkinson@pwgsc-tpsgc.gc.ca
------------------------------------------------------------------- IMPORTANT NOTICE TO SUPPLIERS RE. BID SUBMISSION REQUIREMENTS
Suppliers are strongly encouraged to submit bids electronically using the Canada Post epost Connect application for the subject bid solicitation. This service allows suppliers to submit bids, offers and arrangements electronically to PWGSC Bid Receiving Units. This online service enables the electronic transfer of large files up to Protected B level.
To use epost Connect to submit your bid, or to get more information on its use, please send an email to the Western Region Bid Receiving Unit’s generic address at
tpsgc.pareceptiondessoumissions-apbidreceiving.pwgsc@tpsgc-pwgsc.gc.ca
Faxed bids will be accepted at 1-418-566-6167.
Hard copy (submitted in person or via mail/courier) bids will not be accepted for the subject bid solicitation.
Delivery Date: Above-mentioned
The Crown retains the right to negotiate with suppliers on any procurement.
Documents may be submitted in either official language of Canada.
1. TITLE:
DEVELOPMENT OF AN EFFECTIVE MRNA-BASED AFRICAN SWINE FEVER VACCINE THAT CAN DIFFERENTIATE VACCINATED FROM INFECTED ANIMALS
2. SECURITY:
There is no security requirement associated with the requirement.
3. REQUIREMENT:
The Canadian Food Inspection Agency has a requirement for the Development of an effective mRNA-based African swine fever vaccine that can differentiate vaccinated from infected animals.
African swine fever (ASF) is a highly-fatal, hemorrhagic viral disease that affects members of the Suidae family. Currently, there is no commercially effective vaccine or treatment for ASF and therefore it can have devastating consequences for swine industry in ASF free countries due to high mortality and trade restrictions.
Currently the most effective experimental vaccines for ASF are live attenuated vaccines. Multiple different live attenuated vaccines have been demonstrated to provide protection against ASF. Despite their ability to elicit protective immunity, these vaccines suffer from several drawbacks. Messenger RNA (mRNA) based vaccines have been able to elicit protective immunity consisting of both antibody and cellular immunity in both humans and pigs.
mRNA vaccines can be generated in three different forms; conventional, self-amplifying or trans-amplifying. In order to decide the best form of mRNA vaccine that will work in pigs, we will first express the highly immunogenic ASFV protein p72. Antibodies to ASFV p72 will be measured using serological assays (ELISA).
Objective: In this study we propose to generate an mRNA vaccine which express 15 different antigens of ASFV, and test them in vaccination-challenge experiments at the National Centre for Foreign Animal disease (NCFAD), Winnipeg, Canada. The mRNA vaccines will be designed, produced and supplied to the NCFAD by a contractor.
To qualify a bid will have to consist of no less than 80% of goods and/or services of Canadian origin.
4. EVALUATION AND SELECTION:
Mandatory technical evaluation criteria are included in Annex "C" of the solicitation.
A bid must comply with the requirements of the bid solicitation and meet all mandatory technical evaluation criteria to be declared responsive. The responsive bid with the lowest evaluated price will be recommended for award of a contract.
5. OWNERSHIP OF INTELLECTUAL PROPERTY:
Any intellectual property arising from the performance of the Work under the Contract will vest in Canada.
6. PERIOD OF CONTRACT:
It is anticipated the contract will be effective from date of award to 2023-12-31.
------------------------------------------------------------------ Contracting Authority
Lorraine Jenkinson Procurement Specialist Public Works and Government Services Canada Procurement Branch, Western Region Canada Place, Suite 1000 9700 Jasper Avenue NW Edmonton AB, T5J 4C3
Telephone: 587-337-2458 Facsimile: 780-497-3510 E-mail address: lorraine.jenkinson@pwgsc-tpsgc.gc.ca
------------------------------------------------------------------- IMPORTANT NOTICE TO SUPPLIERS RE. BID SUBMISSION REQUIREMENTS
Suppliers are strongly encouraged to submit bids electronically using the Canada Post epost Connect application for the subject bid solicitation. This service allows suppliers to submit bids, offers and arrangements electronically to PWGSC Bid Receiving Units. This online service enables the electronic transfer of large files up to Protected B level.
To use epost Connect to submit your bid, or to get more information on its use, please send an email to the Western Region Bid Receiving Unit’s generic address at
tpsgc.pareceptiondessoumissions-apbidreceiving.pwgsc@tpsgc-pwgsc.gc.ca
Faxed bids will be accepted at 1-418-566-6167.
Hard copy (submitted in person or via mail/courier) bids will not be accepted for the subject bid solicitation.
Delivery Date: Above-mentioned
The Crown retains the right to negotiate with suppliers on any procurement.
Documents may be submitted in either official language of Canada.